Financial Projections - The company expects to achieve operating revenue of between 248 million and 254 million yuan in 2024, an increase of 31.40% to 34.58% compared to 188.73 million yuan in the previous year[3]. - The projected net profit attributable to the parent company for 2024 is between 90 million and 130 million yuan, marking a turnaround from a loss of 396 million yuan in the previous year[3]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 450 million and 490 million yuan[3]. Research and Development - Research and development investment is projected to be between 920 million and 960 million yuan, a decrease of 21.14% to 24.43% compared to 1.217 billion yuan in the previous year[3]. - The company is actively controlling operating costs and improving R&D efficiency to achieve cost reduction and efficiency enhancement[9]. Earnings Forecast - The earnings forecast has not been audited by registered accountants and is based on preliminary calculations by the company's financial department[10]. - The company has not identified any significant uncertainties that could affect the accuracy of the earnings forecast[10]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[11]. Revenue Drivers - The company attributes the expected revenue increase to stable sales of its core product and growth in sales from other listed products[9].
神州细胞(688520) - 2024 Q4 - 年度业绩预告(更正)